Screener
Lexicon Pharmaceuticals LXRX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Lexicon Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
FAQ
- What is Lexicon Pharmaceuticals's debt-to-equity?
- Lexicon Pharmaceuticals (LXRX) reported debt-to-equity of 0.3× in Q2 2026.
- How has Lexicon Pharmaceuticals's debt-to-equity changed year-over-year?
- Lexicon Pharmaceuticals's debt-to-equity decreased by 28.5% year-over-year, from 0.5× to 0.3×.
- What is the long-term trend for Lexicon Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's debt-to-equity has grown at a 49.3% compound annual growth rate (CAGR), from 0.1× to 0.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Lexicon Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude